U.S. Markets closed

MMRGlobal to Add Canada to Portfolio of Issued Patents, Company's Health IT IP to Include All of North America

LOS ANGELES, CA--(Marketwire - Mar 12, 2013) -  MMRGlobal, Inc. ( OTCQB : MMRF ) ("MMR") today announced that through its wholly owned subsidiary, MyMedicalRecords, Inc., the Company has received a Notice of Allowance from the Canadian Intellectual Property Office for Application Number 2,615,128 directed toward its "Method and System for Providing Online Medical Records." This adds to the Company's international footprint where it has patents issued, pending, and applied for in 13 countries of commercial interest which, in addition to the United States, currently include Australia, Singapore, New Zealand, Canada, Mexico, Japan, Hong Kong, South Korea, Israel and various European nations. The Company began receiving the first of its North American patents with seven issued in the U.S. starting in 2011, Mexico was added in April 2012, and now Canada based on today's announcement. MMRGlobal is a leading provider of Personal Health Records (PHRs), MyEsafeDepositBox storage solutions and MMRPro document management and imaging systems for healthcare professionals. The Company's health IT patent portfolio, which is separate from its biotech intellectual property assets, involves inventions pertaining to Personal Health Records, Patient Portals and other Electronic Health Record systems.

"I am very excited about Canada becoming part of our international footprint," said Robert H. Lorsch, MMRGlobal CEO. "It was clear at last week's HIMSS Conference in New Orleans (http://blog.mmrglobal.com) that this year's focus in health IT is all about patient engagement and interoperability. With patents in 13 countries around the world, a joint venture agreement in China, and Meaningful Use Stage 2 being implemented here in the U.S., MMR's Personal Health Record is uniquely positioned to be the global go anywhere brand. Also evident coming out of HIMSS was that the biggest players in the world are collaborating on ways to place PHRs in the hands of the patient, and as they do, MMR is positioned to be in the middle of it all as most roads appear to run through MMR's IP."

According to John Goodhue at McKee, Voorhees & Sease (www.ipmvs.com), the Company's patent prosecution counsel since the filing of MMR's first patent applications in 2005, "The Canadian allowance includes 40 claims that correspond with numerous claims already granted in the U.S. In addition to offering its own products, MMR has licensed its health information technology patents to a growing number of companies. The resulting Canadian patent will assist in driving further licensing efforts in Canada or as part of international or worldwide licenses."

In the U.S., MMR's patents are covered through U.S. Patent Serial Nos. 8,352,287; 8,121,855; 8,117,646; 8,117,045; 8,301,466; 8,321,240; and 8,352,288; and there are also nearly 400 claims as well as additional applications and continuation applications. The Company's patents also contain claims directed to Web-based services that provide access to and collection of health records from service providers, including, but not limited to, retail pharmacies and laboratory systems as well as hospitals, physicians and other healthcare professionals, using email, facsimile, file upload and/or voice.

MMRGlobal was featured in a Special Report dated January 22, 2013 (http://michaelbass.com/PDF/Patent_Valuation.pdf), published by the Michael Bass Research Group on the Personal Health Records market, with particular emphasis on MMRGlobal's MyMedicalRecords health information technology global patent portfolio which at that time did not include issuances in Japan or Canada. According to the analysis, the report included a valuation of the Company's U.S. patents of between $600 million to $1.1 billion based on what is described as conservative estimates and that the market will reach a projected GDP value of $19 billion.

About MMRGlobal, Inc.
MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit www.mmrglobal.com. View demos and video tutorials of the Company's products and services at www.mmrtheater.com.

Forward-Looking Statements
All statements in this press release that are not strictly historical in nature, including, without limitation, intellectual property licenses, potential intellectual property enforcement actions, infringement claims or litigation, and future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "potential," "intend," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Actual outcomes of intellectual property enforcement actions, infringement claims, litigation or licensing transactions, results of operations and the timing of selected events may differ materially from the results predicted, and any reported results should not be considered as an indication of future performance. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property enforcement actions, claims of intellectual property infringement and general intellectual property litigation; our ability to maintain, develop, monetize and protect our patent portfolio for both the Company's health IT and biotechnology intellectual property assets in the U.S. and internationally; the timing of milestone payments in connection with licensing our intellectual property; our ability to establish and maintain strategic relationships; changes in our relationships with our licensees; the risk the Company's products are not adopted or viewed favorably by the healthcare community and consumer retail market; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; the timing and volume of sales and installations; the length of sales cycles and the installation process; the market's acceptance of new product and service introductions; competitive product offerings and promotions; changes in government laws and regulations including the 2009 HITECH Act and changes in Meaningful Use and the 2010 Affordable Care Act; future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; the possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; risks related to a security breach by third parties; risks associated with recruitment and retention of key personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company's filings with the Securities and Exchange Commission, including disclosures about the Company's relationship with the Michael Bass Group since 2009. The Company is providing this information as of the date of this release and, except as required by applicable law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.